WebMay 12, 2024 · SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, May 12, 2024 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical ... WebWho We Are. Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates to ...
Gracell Biotechnologies Announces Pricing of Initial Public …
WebMar 9, 2024 · Net loss attributable to Gracell Biotechnologies Inc.’s ordinary shareholders (72,992) (200,856) (274,633) (42,089) Other comprehensive loss. Foreign currency … WebMay 19, 2024 · Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. income tax cut off date
Gracell Biotechnologies Presents Clinical Data for FasTCAR-T …
WebGracell Biotechnologies has raised a total of $185M in funding over 3 rounds. Their latest funding was raised on Oct 28, 2024 from a Series C round. Gracell Biotechnologies is … WebMay 17, 2024 · Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. WebJan 13, 2024 · All of the ordinary shares represented by ADSs are being offered by Gracell. The ADSs were approved for listing on The Nasdaq Global Market and began trading on January 8, 2024, under the ticker symbol "GRCL." The offering is expected to close on January 12, 2024, subject to the satisfaction of customary closing conditions. income tax cut off 2021 ireland